Anthem Biosciences Ltd
Anthem Biosciences Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #63 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Anthem Biosciences Ltd Q2 FY27 key numbers
- Revenue
- Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26.
As stated in Anthem Biosciences Ltd's Q2 FY27 investor presentation · published 3 Nov 2026. Reported figures, not investment advice.
Based on Anthem Biosciences Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Q2FY27 EBITDA: ₹3,304 Mn, up 24.1% YoY from ₹2,661 Mn in Q2FY26.
From Anthem Biosciences Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.
How did Anthem Biosciences' revenue grow in the September 2026 quarter?
- Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4).
- CRDMO business revenue: ₹5,093 Mn, up 9.2% YoY from ₹4,662 Mn in Q2FY26 (Page 4).
- Specialty Ingredients revenue: ₹848 Mn, up 0.6% YoY from ₹843 Mn in Q2FY26 (Page 4).
2 more points from Anthem Biosciences Ltd's call on revenue
Create a free account to keep reading this call
What happened to Anthem Biosciences' margins in Q2 FY27?
See what Anthem Biosciences Ltd said on profitability & margins — free account, 30 seconds.
What capex is Anthem Biosciences planning?
2 more points from Anthem Biosciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Anthem Biosciences raising money or cutting debt?
See what Anthem Biosciences Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Anthem Biosciences' order book?
See what Anthem Biosciences Ltd said on order book & pipeline — free account, 30 seconds.
Anthem Biosciences Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹611 Cr, net profit ₹190 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anthem Bioscienc's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- Emcure Pharma (Q2 FY27)
Q2FY27 Revenue from Operations: INR 28,205 Mn, up 24.3% YoY (Page 9). Key investor presentation takeaways from Emcure Pharmaceuticals Ltd's Q2 FY27 investor pre
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anthem Biosciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anthem Biosciences Ltd Q2 FY27 results?
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Q2FY27 EBITDA: ₹3,304 Mn, up 24.1% YoY from ₹2,661 Mn in Q2FY26.
What is Anthem Biosciences Ltd share price analysis?
Anthem Biosciences Ltd currently shows a neutral. The stock trades at a P/E of 79.3 with a market cap of ₹47,067 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Anthem Biosciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.